IP Library Granted Patent US 11,903,835
Granted Patent B2
US 11,903,835 · App. 16/803,208 · Granted Feb 20, 2024

Demineralized bone fiber composition for use in minimally invasive surgery

Inventors: Andrew J. Carter (Stow, MA); Nelson L Scarborough (Andover, MA); Oliver Scarborough (Andover, MA)
Assignee: THERACELL, LLC
A61F2/30965A61F2/28A61F2/3094A61F2/4601A61L27/365A61L27/3608A61F2002/2835A61F2002/4627A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,903,835
App. No.
16/803,208
Granted
Feb 20, 2024
Kind
B2
Abstract

A bone repair composition and methods thereof include bone fibers made from cortical bone in which a plurality of bone fibers are made into various implant shapes conducive to introduction into a patient through minimally invasive surgery. The bone fiber compositions may be in the form of a pellet or cylinder. A method includes producing the bone fiber graft efficiently with control of key parameters of cohesiveness, rehydration and swelling of the bone fiber graft. Another method includes introducing the bone fiber graft into the cannula efficiently. A method is also provided to allow introduction of a bone graft into a patient by placing the implant in a tube and expelling it through the action of a plunger.

Claims (23)

1. A device for delivering one or more bone fiber pellets having x-ray opacity to a target surgical site, the device comprising:

a holder with a plurality of cavities each having a cavity lumen extending therethrough between a first open end to a second open end, the cavity lumen configured to receive a bone fiber pellet comprising a contrast agent;

an elongated member forming a delivery tube positioned at an interface of the holder and the elongated member at the second open end of the cavity lumen, the delivery tube between a first tube open end aligned with the second open end of the cavity lumen and a second tube open end; and

a push rod receivable through the first open end corresponding to the cavity lumen positioned at the interface of the holder and the elongated member, the push rod configured to push the bone fiber pellet into the delivery tube and out of the device to the target surgical site.

2. The device of claim 1 , wherein the contrast agent is a water soluble non-ionic x-ray contrast agent.

3. The device of claim 1 , wherein the contrast agent is an iodinated aromatic compound.

4. The device of claim 3 , wherein the iodinated aromatic compound has one or more aromatic nuclei that are at least triiodo-substituted.

5. The device of claim 3 , wherein the iodinated aromatic compound is selected from metrizamide, iopamidol, iomeprol, iopromide, ioversol, iohexol, iopentol, ioxilan, iogulamide, ioglucol, ioglucamide, ioglunide, MP-7011, MP-7012, MP-10007, VA-7-88, CAS No. 79944-51-7, iosimide, iocibidol, Cas. No. 103876-29-5, iofratol, iodixanol, iotrol, iotasul, or iodecol.

6. The device of claim 2 , wherein the water soluble non-ionic x-ray contrast agent is selected from iotrolan, ioxaglate, iodecimol, iosarcol, iotusal, ioxilane, or ofrotal.

7. The device of claim 2 , wherein the water soluble non-ionic x-ray contrast agent is iohexol or iodixanol.

8. The device of claim 1 , wherein the contrast agent is barium sulphate.

9. The device of claim 1 , further comprising a removable cap for covering the second tube open end.

10. The device of claim 1 , wherein the push rod has a length greater than a length of the elongated member.

11. The device of claim 1 , wherein the cavity lumen is metallic.

12. The device of claim 1 , further comprising one or more bone fiber pellets.

13. The device of claim 1 , wherein the plurality of cavities includes up to 6 cavities.

14. A method of delivering a bone fiber pellet having x-ray opacity to a target surgical site, the method comprising using the device of claim 1 .

15. The method of claim 14 , wherein the contrast agent is a water soluble non-ionic x-ray contrast agent.

16. The method of claim 14 , wherein the contrast agent is an iodinated aromatic compound.

17. The method of claim 14 , wherein the contrast agent is selected from metrizamide, iopamidol, iomeprol, iopromide, ioversol, iohexol, iopentol, ioxilan, iogulamide, ioglucol, ioglucamide, ioglunide, MP-7011, MP-7012, MP-10007, VA-7-88, CAS No. 79944-51-7, iosimide, iocibidol, Cas. No. 103876-29-5, iofratol, iodixanol, iotrol, iotasul, iodecol, iotrolan, ioxaglate, iodecimol, iosarcol, iotusal, ioxilane, iofrotal, iohexol, or iodixanol.

18. The method of claim 14 , wherein the contrast agent is barium sulphate.

19. The method of claim 14 , wherein the bone fiber pellet comprises the contrast agent prior to the bone fiber pellet being received by the cavity lumen of the device or the contrast agent is added to the bone fiber pellet after the bone fiber pellet has been received by the cavity lumen of the device.

20. A method of delivering a bone fiber pellet having x-ray opacity to a target surgical site, the method comprising using the device of claim 12 .

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2025
From: THERACELL, LLC
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.
Reel/Frame 072388/0197 →
SECURITY INTEREST Recorded Sep 18, 2025
From: ISTO TECHNOLOGIES II, LLC; ADVANCED BIOLOGICS LLC,; ARTERIOCYTE MEDICAL SYSTEMS, INC.; THERACELL, LLC
To: GOLUB CAPITAL MARKETS LLC
Reel/Frame 072300/0216 →
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2025
From: BARINGS FINANCE LLC, AS COLLATERAL AGENT
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
Reel/Frame 072274/0408 →
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2023
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: ISTO TECHNOLOGIES II, LLC
Reel/Frame 065269/0604 →
SECURITY INTEREST Recorded Oct 18, 2023
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
To: BARINGS FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065271/0059 →
CHANGE OF NAME Recorded Oct 11, 2023
From: THERACELL, INC.
To: THERACELL, LLC
Reel/Frame 065219/0102 →
SECURITY INTEREST Recorded Apr 4, 2022
From: THERACELL, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 059486/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2020
From: CARTER, ANDREW J.; SCARBOROUGH, NELSON L.; SCARBOROUGH, OLIVER
To: THERACELL, INC.
Reel/Frame 052664/0046 →